Literature DB >> 3126306

Efficacy of low doses of praziquantel for Schistosoma mansoni and S. haematobium.

P Taylor1, H M Murare, K Manomano.   

Abstract

The shortage of available information on the impact of low doses of praziquantel was remedied by a trial of 0, 10, 20, 30 and 40 mg kg-1 against double infections of Schistosoma haematobium and S. mansoni in a rural area of Zimbabwe. No significant differences were found in egg reduction between 20-40 mg kg-1 for S. haematobium and between 30-40 mg kg-1 for S. mansoni. It is suggested that morbidity control can be achieved with lower dosages of praziquantel than currently recommended.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3126306

Source DB:  PubMed          Journal:  J Trop Med Hyg        ISSN: 0022-5304


  10 in total

1.  Development and validation of a 'tablet pole' for the administration of praziquantel in sub-Saharan Africa.

Authors:  A Montresor; D Engels; L Chitsulo; D A Bundy; S Brooker; L Savioli
Journal:  Trans R Soc Trop Med Hyg       Date:  2001 Sep-Oct       Impact factor: 2.184

2.  The WHO dose pole for the administration of praziquantel is also accurate in non-African populations.

Authors:  A Montresor; P Odermatt; S Muth; F Iwata; Y A Raja'a; A M Assis; A Zulkifli; N B Kabatereine; A Fenwick; S Al-Awaidy; H Allen; D Engels; L Savioli
Journal:  Trans R Soc Trop Med Hyg       Date:  2005-01       Impact factor: 2.184

3.  Treatment of schistosomiasis in African infants and preschool-aged children: downward extension and biometric optimization of the current praziquantel dose pole.

Authors:  José C Sousa-Figueiredo; Martha Betson; J Russell Stothard
Journal:  Int Health       Date:  2012-06       Impact factor: 2.473

4.  Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya.

Authors:  C H King; E M Muchiri; J H Ouma
Journal:  Emerg Infect Dis       Date:  2000 Nov-Dec       Impact factor: 6.883

Review 5.  Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-a meta-analysis of comparative and non-comparative clinical trials.

Authors:  Julien Zwang; Piero L Olliaro
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

Review 6.  Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged children: a meta-analysis.

Authors:  Julien Zwang; Piero Olliaro
Journal:  Parasit Vectors       Date:  2017-01-26       Impact factor: 3.876

7.  Accuracy of the WHO praziquantel dose pole for large-scale community treatment of urogenital schistosomiasis in northern Mozambique: Is it time for an update?

Authors:  Pedro H Gazzinelli-Guimaraes; Neerav Dhanani; Charles H King; Carl H Campbell; Herminio O Aurelio; Josefo Ferro; Rassul Nala; Alan Fenwick; Anna E Phillips
Journal:  PLoS Negl Trop Dis       Date:  2018-11-15

8.  Efficacy of praziquantel has been maintained over four decades (from 1977 to 2018): A systematic review and meta-analysis of factors influence its efficacy.

Authors:  Mizuho Fukushige; Margo Chase-Topping; Mark E J Woolhouse; Francisca Mutapi
Journal:  PLoS Negl Trop Dis       Date:  2021-03-17

Review 9.  Drugs for treating urinary schistosomiasis.

Authors:  Christine V Kramer; Fan Zhang; David Sinclair; Piero L Olliaro
Journal:  Cochrane Database Syst Rev       Date:  2014-08-06

10.  Field test of the 'dose pole' for praziquantel in Zanzibar.

Authors:  A Montresor; D Engels; M Ramsan; A Foum; L Savioli
Journal:  Trans R Soc Trop Med Hyg       Date:  2002 May-Jun       Impact factor: 2.184

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.